Daré Bioscience, Inc. Expands Leadership Team, Appointing Mary Jarosz, RPh, to Global Head of Regulatory Affairs
SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Mary Jarosz, RPh, to the newly created role of Global Head of Regulatory Affairs.
“Mary Jarosz is an accomplished regulatory leader that brings a highly relevant set of skills to Daré. I have had the pleasure of working with Mary at a prior company, and she has supported Daré in a consulting capacity during the last year. I am thrilled to now add her to our accomplished leadership team as an employee,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Ms. Jarosz has presided over regulatory affairs at both large and specialty pharmaceutical companies. Her extensive oversight of clinical development strategies and global regulatory submissions, as well as her deep knowledge of fast-track, 505(b)(2), device and orphan drug applications, will allow us to more effectively execute against our regulatory strategy.”
Ms. Jarosz has over 20 years of experience in the pharmaceutical industry. Prior to her appointment as Global Head of Regulatory Affairs, Ms. Jarosz served as the Senior Vice President of Regulatory Affairs & Quality Assurance at Evofem Biosciences. Prior to joining Evofem Biosciences, Ms. Jarosz held senior-level roles at WomanCare Global, a UK based global women’s health entity, where she successfully registered a number of women’s reproductive healthcare products and devices, and at the pharmaceutical company Abbott Laboratories where she spent several years working in global regulatory affairs.
“I am truly excited to join the leadership team of Daré Bioscience,” said Ms. Jarosz. “I believe that Daré is on the forefront of innovation in women’s health with a portfolio of novel and differentiated product candidates. I look forward to working to advance these products through the development and regulatory approval process, thereby increasing the options available to women.”
Ms. Jarosz has published in several journals, including Regulatory Affairs Focus and ESRA Rapporteur, has presented at regulatory conferences and served as a guest lecturer for several universities. She was Head of Publications and Publicity for The Organization for Professionals in Regulatory Affairs (TOPRA), North America Leadership Team. Prior to her experience in the pharmaceutical industry, Ms. Jarosz was a Clinical Pharmacist at Michael Reese Hospital in Chicago, Illinois and a Pediatric Intensive Care Clinical Pharmacist at the University of Wisconsin Hospital. Ms. Jarosz holds a Baccalaureate of Science in Pharmacy, is an appointed Fellow of TOPRA (FTOPRA), is RAC certified, and is a Registered Pharmacist in the states of Illinois and Wisconsin.
For more information on Daré including its portfolio of women’s health product candidates, please visit www.darebioscience.com.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive and sexual health. The company’s mission is to identify, develop and bring to market a diverse portfolio of novel, differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women in the areas of contraception, vaginal health, sexual health, and fertility. Daré’s product portfolio includes two potential first-in-class candidates currently in clinical development: Ovaprene®, a non-hormonal, monthly contraceptive vaginal ring and Topical Sildenafil (SST-6007), a potential treatment for female sexual arousal disorder utilizing the same active ingredient as Viagra®. To learn more about Daré’s full portfolio of women’s health products, and mission to deliver novel therapies for women, please visit www.darebioscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Daré's expectations regarding its ability to effectively execute against its regulatory strategy and advancing its products through the development and regulatory approval process. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, and other factors discussed in the "Risk Factors" section of Daré's Report on Form 10-K filed with the Securities and Exchange Commission on March 28, 2018. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Daré's reports to the Securities and Exchange Commission, including Daré's reports on Forms 10-Q, 8-K and 10-K. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. Daré specifically disclaims any obligation to update any forward-looking statements included in this press release.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Ami Bavishi
Burns McClellan
abavishi@burnsmc.com
212-213-0006
OR
Media on behalf of Daré Bioscience, Inc.:
Amanda Guisbond
Canale Communications
amanda@canalecomm.com
781-405-8775
Source: Daré Bioscience